Abstract 4504: Retrospective study of clinicopathologic factors associated with <i>ALK</i> rearrangement and survival outcome in Chinese patients with NSCLC

Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jianwei Xuan(Pfizer (United States)), Zhi Xie, Hong-Xia Tian, Jin‐Ji Yang(Guangdong Academy of Medical Sciences), C. Blanckmeister(Pfizer (United States)), Jie Chen(Shandong University of Technology), Yan‐Hui Liu(Hainan University), Hong‐Hong Yan(Sun Yat-sen University), Luo Xin-lan(Guangdong General Hospital), Su Jian
Cancer Research
April 1, 2012
10.1158/1538-7445.am2012-4504
Cited by 3

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k